Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.68 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.68 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.68 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6773960 | 0.83 | PDE4B (0.46) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2052162 | 0.81 | PDE4A (0.70) | PDE4APDE4BPDE4CPDE4DP2RX7 | |
| Awd-12-281 SCHEMBL29413256 | 0.81 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DP2RX7 | |
| Awd-12-281 SCHEMBL155120 | 0.81 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DP2RX7 | |
| Awd-12-281 SCHEMBL5638136 | 0.80 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DIDO1 | |
| Awd-12-281 SCHEMBL5638122 | 0.80 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DIDO1 | |
| SCHEMBL7563667 | 0.78 | PDE4B (0.42) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5637675 | 0.75 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DPOLB | |
| SCHEMBL3101476 | 0.75 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4DIDO1 | |
| SCHEMBL6255980 | 0.74 | PDE4A (0.89) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7161009-B2 | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation | ELBION AG (DE) | 2007-01-09 | — | — | US | claimed |
| US-20040220183-A1 | inhibiting tumor necrosis factor; respiratory system disorders; prevent neutrophil infiltration in lungs; skin disorders | HOFGEN NORBERT (DE) | 2004-11-04 | — | — | US | claimed |
| US-RE38624-E1 | ALSO INHIBITORS OF TUMOR NECROSIS FACTOR ALPHA; USED FOR TREATING EOSINOPHIL-RELATED CONDITION, CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ELBION AG (DE) | 2004-10-12 | — | — | US | claimed |
| EP-1076657-B1 | NEW HYDROXYINDOLES, THEIR USE AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING SAME | ELBION AG (DE) | 2004-08-04 | — | — | EP | claimed |
| US-6602890-B2 | N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5 -hydroxyindol-3-yl)-2-oxoacetamide, for example; treating eosinophil-related conditions, including chronic obstructive pulmonary disease | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2003-08-05 | — | — | US | claimed |
| US-20030134876-A1 | Inhibiting TNF alpha | ELBION AG (DE) | 2003-07-17 | — | — | US | claimed |
| US-20020137745-A1 | N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5 -hydroxyindol-3-yl)-2-oxoacetamide, for example; treating eosinophil-related conditions, including chronic obstructive pulmonary disease | ELBION AG (DE) | 2002-09-26 | — | — | US | claimed |
| US-20020119971-A1 | Antiinflammatory agents; skin disorders; central nervous system disorders | ELBION AG (DE) | 2002-08-29 | — | — | US | claimed |
| US-20020115651-A1 | Such as N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5-hydroxyindol-3-yl)-2 -oxoacetamide; for treatment of eosinophil-related disorders and chronic obstructive pulmonary disease | ELBION AG (DE) | 2002-08-22 | — | — | US | claimed |
| US-20020111351-A1 | Antiinflammatroy agents; antiallergens | ELBION AG (DE) | 2002-08-15 | — | — | US | claimed |
| US-6251923-B1 | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2001-06-26 | — | — | US | claimed |
| EP-2120936-B1 | NOVEL METHODS | ALMIRALL SA (ES) | 2011-06-22 | — | — | EP | disclosed |
| CN-1321981-C | Hydroxyindoles, their use as phosphodiesterase 4 inhibitors and process for their preparation | ELBION AG (DE) | 2007-06-20 | — | — | CN | disclosed |
| US-7161009-B2 | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation | ELBION AG (DE) | 2007-01-09 | — | — | US | disclosed |
| EP-1475377-B1 | Derivatives of indole and their use as phosphodiesterase 4 inhibitors | ELBION AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| US-6251923-B1 | Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation | ARZNEIMITTELWERK DRESDEN GMBH (DE) | 2001-06-26 | — | — | US | disclosed |
| WO-2000014075-A1 | PROCESS FOR MAKING 2-(2-HYDROXY-4-ALKOXYPHENYL)-4,6-BISARYL-1,3,5-TRIAZINES | CYTEC TECHNOLOGY CORP. (US) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000014074-A1 | PROCESS FOR MAKING 2-HYDROXY-4-ALKOXYPHENYL OR 2,4-DIHYDROXYPHENYL SUBSTITUTED 1,3,5-TRIAZINE UV ABSORBERS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2000-03-16 | — | — | WO | disclosed |
| US-4309500-A | CONTAINING ABSORBER OF ULTRAVIOLET LIGHT | FUJI PHOTO FILM CO., LTD. (JP) | 1982-01-05 | — | — | US | disclosed |
| US-4191576-A | SULFONYL-SUBSTITUTED PYRROLIDINE, OXAZOLIDINE OR THIAZOLIDINE | FUJI PHOTO FILM CO., LTD. (JP) | 1980-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111351-A1 | Antiinflammatroy agents; antiallergens | MPO, LTA4H, PADI4 | PDE4A 8/4885PDE4B 17/4885PDE4C 49/4885 |
| US-20020119971-A1 | Antiinflammatory agents; skin disorders; central nervous system disorders | PDE4A, TPH1, PDE12 | PDE4A 1/4885PDE4B 4/4885PDE4C 7/4885 |
| US-20030134876-A1 | Inhibiting TNF alpha | TNF, NFKBIA, PDE4A | PDE4A 3/4885PDE4B 6/4885PDE4C 11/4885 |
| US-20020115651-A1 | Such as N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5-hydroxyindol-3-yl)-2 -oxoacetamide; for treatment of eosinophil-related disorders and chronic obstructive pulmonary disease | EPX, SERPINB1, ELANE | PDE4A 5/4885PDE4B 7/4885PDE4C 14/4885 |
| US-20040220183-A1 | inhibiting tumor necrosis factor; respiratory system disorders; prevent neutrophil infiltration in lungs; skin disorders | MMP8, MPO, TNF | PDE4A 7/4885PDE4B 21/4885PDE4C 60/4885 |
| US-20020137745-A1 | N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5 -hydroxyindol-3-yl)-2-oxoacetamide, for example; treating eosinophil-related conditions, including chronic obstructive pulmonary disease | EPX, CCL11, PDE12 | PDE4A 6/4885PDE4B 7/4885PDE4C 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.